Drugs / Human CD19-CD22 Targeted T Cells Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05651178 | Aug 2022 → Nov 2024 overdue | lymphoma | Hrain Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human CD19-CD22 Targeted T Cells Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05651178 ↗ |
| Modality | Cell therapy | “Autologous genetically modified anti-CD19/CD22 CAR transduced T cells” NCT05651178 ↗ |
| Route | Intrathecal | “intravenous and intrathecal administration” NCT05651178 ↗ |
| Route | Intravenous | “intravenous and intrathecal administration” NCT05651178 ↗ |
| Target | CD19 | “anti-CD19/CD22 CAR transduced T cells” NCT05651178 ↗ |
| Target | CD22 | “anti-CD19/CD22 CAR transduced T cells” NCT05651178 ↗ |